|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0262 - 0.0348|
|52 Week Range||0.0210 - 0.1400|
|Beta (5Y Monthly)||-14.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RLFTF
RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.
RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) ("Relief"), announced today that it has filed Amendment No. 1 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering of its ordinary shares in the form of American Depositary Shares ("ADSs").
RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (" Relief "), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (" NRx Pharmaceuticals "), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.